Study S000233

A 52-week, Multi-centre, Open-labelled, Randomised (2:1), Parallel-group Trial With an Active Control (Two OADs Combination Therapy) to Evaluate the Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Monotherapy

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT01512108
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 363
Start: 2012-01-10
Primary completion: 2013-04-26
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Diabetes Mellitus, Type 2
Interventions: DRUG:liraglutide; DRUG:oral anti-diabetic drug
Results posted: TRUE
Secondary identifiers: OTHER:U1111-1121-3457; REGISTRY:JapicCTI-121744

Registered primary outcomes

Incidence of Treatment Emergent Adverse Events (AEs) [Week 0 to Week 52 + 7 days]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0011989	Safety and efficacy of the combination of the glucagon-like peptide-1 receptor agonist liraglutide with an oral antidiabetic drug in Japanese patients with type 2 diabetes: Post-hoc analysis of a randomized, 52-week, open-label, parallel-group trial. Kiyosue A, Journal of diabetes investigation	2018	Randomized trial	PMID 28984041 DOI	registry reference RESULT:28984041
R0026134	Liraglutide is effective and well tolerated in combination with an oral antidiabetic drug in Japanese patients with type 2 diabetes: A randomized, 52-week, open-label, parallel-group trial. Kaku K, Journal of diabetes investigation	2016	Randomized trial	PMID 26816604 DOI	cites ClinicalTrials.gov:NCT01512108; registry reference RESULT:26816604